Barclays PLC Biocryst Pharmaceuticals Inc Call Options Transaction History

Barclays PLC

15 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $41,300 - $67,900	10,000 New	10,000 $62,000
Q2 2021 Aug 13, 2021	SELL	$9.5 - $17.24 $161,500 - $293,080	-17,000 Reduced 33.07%	34,400 $544,000
Q1 2021 May 13, 2021	SELL	$7.37 - $13.61 $125,290 - $231,370	-17,000 Reduced 24.85%	51,400 $523,000
Q3 2020 Nov 12, 2020	SELL	$3.43 - $5.53 $287,091 - $462,861	-83,700 Reduced 55.03%	68,400 $235,000
Q2 2020 Aug 12, 2020	BUY	$1.9 - $5.61 $263,150 - $776,985	138,500 Added 1018.38%	152,100 $725,000
Q4 2019 Feb 10, 2020	BUY	$1.59 - $3.45 $16,854 - $36,570	10,600 Added 353.33%	13,600 $47,000
Q3 2019 Nov 14, 2019	SELL	$2.5 - $3.73 $3,750 - $5,595	-1,500 Reduced 33.33%	3,000 $9,000
Q2 2019 Aug 14, 2019	BUY	$2.91 - $9.15 $9,312 - $29,280	3,200 Added 246.15%	4,500 $17,000
Q1 2019 May 15, 2019	SELL	$7.38 - $9.72 $251,658 - $331,452	-34,100 Reduced 96.33%	1,300 $11,000
Q4 2018 Feb 14, 2019	BUY	$6.51 - $9.6 $31,248 - $46,080	4,800 Added 15.69%	35,400 $286,000
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $46,920 - $67,915	8,500 Added 38.46%	30,600 $233,000
Q2 2018 Aug 14, 2018	BUY	$4.6 - $6.52 $55,199 - $78,240	12,000 Added 118.81%	22,100 $127,000
Q1 2018 May 15, 2018	SELL	$4.35 - $5.82 $131,370 - $175,764	-30,200 Reduced 74.94%	10,100 $48,000
Q4 2017 Feb 14, 2018	BUY	$4.16 - $5.33 $35,776 - $45,838	8,600 Added 27.13%	40,300 $198,000
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $129,969 - $189,249	31,700	31,700 $166,000

280

172M

625K

739K

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.